Cerus CERS
Cerus reported a net loss of $550,000 for the three months ended Sep 30, 2026.
Quarterly report, 4 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-443694
- Revenue: $57.71 million for the three months ended Sep 30, 2026.
- Net loss: $550,000 for the three months ended Sep 30, 2026.
- Diluted EPS: $0.00 for the three months ended Sep 30, 2026.
- Cash and equivalents: $16.35 million at Sep 30, 2026.
Written from the 10-Q on EDGAR. Check the filing before you rely on it.
What changed since last quarter
4 new risk factors · 4 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $57.71M | $57.44M | +0.5% |
| Operating income and margin | $383K · 0.7% | −$1.86M · -3.2% | +121%, margin +3.9 pts |
| Net income | −$550K | −$2.94M | +81% |
| Operating cash flow | $3.01M | −$2.66M | +213% |
| Cash | $16.35M | $17.98M | −9.1% |
New risk factors (4)
- • ability of blood center manufacturers to maintain production of IFC at sufficient quantities and at acceptable quality levels;
- In many countries in Western Europe and in Japan, various national blood transfusion services or Red Cross organizations collect, store and distribute virtually all of their respective nations' blood and blood components supply and often times use their national public procurement processes to purchase our products…
- In order to increase and diversify manufacturing capacity, our manufacturing partners have in the past, and may in the future, require us to pay for capital investments in whole or in-part in order to offset the impact of cash flows and risk. To meet the growing demand for our products and to invest in future quality…
- Agreement and Revolving Loan Credit Agreement. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.
Removed risk factors (4)
- • ability to contract with, maintain and add additional blood center manufacturers for the production of IFC and for the contracted blood center manufacturing partners to produce IFC at sufficient quantities and at acceptable quality levels or for other blood centers to contract with us for the purchase of kits and…
- Governance requirements to its suppliers. Should the American Red Cross or other customers impose such requirements to our business, we may be unable to satisfy the requirements without significant disruption to our operations and incurrence of costs, if at all.
- Given the current blood component shortage, increased collection volumes may not be achievable or use of INTERCEPT may be considered less efficient than other operating practices, particularly in regions such as the U.S. where we do not maintain a seven day platelet storage claim. Given the scarcity of platelets in…
- We are also planning a prospective, open-label, controlled Phase 2 study designed to determine whether INTERCEPT RBC transfusions into patients with pre-existing antibodies to INTERCEPT RBCs will result in increased antibody titer indicative of a secondary immune response. Subjects will have samples drawn…
The reading, claim by claim
0 of 5 claims matched the filing text.
Not found in the filing text
- For the quarter ended September 30, 2026, CERUS CORP reported: Revenue $57.7 million.
- Net income -$550,000.
- Operating margin 0.7%.
- Net margin -1.0%.
- Revenue change from a year earlier +9.5%.
From the filing
Item 1.
Item 1.
Financial Statements
1
Condensed Consolidated Balance Sheets – September 30, 2026 and December 31, 2025
1
Condensed Consolidated Statements of Operations – Three and nine months ended September 30, 2026 and 2025
2
Condensed Consolidated Statements of Comprehensive Loss – Three and nine months ended September 30, 2026 and 2025
3
Condensed Consolidated Statements of Stockholders' Equity – Three and nine months ended September 30, 2026 and 2025
4
Condensed Consolidated Statements of Cash Flows – Nine months ended September 30, 2026 and 2025
6
Notes to Condensed Consolidated Financial Statements
7
ITEM 1. FINANC IAL STATEMENTS
ITEM 1. FINANC IAL STATEMENTS CERUS CORPORATION CONDENSED CONSOLIDA TED BALANCE SHEETS
(in thousands)
September 30,
December 31,
2026
2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
16,350
$
19,961
Short-term investments
40,759
62,918
Accounts receivable, net
30,560
30,374
Current inventories
64,689
56,101
Prepaid and other current assets
4,212
5,030
Total current assets
156,570
174,384
Non-current assets:
Property and equipment, net
9,423
9,204
Operating lease right-of-use assets
8,797
10,124
Goodwill
1,316
1,316
Restricted cash
625
639
Non-current inventories
15,635
15,143
Other assets
12,363
11,049
Total assets
$
204,729
$
221,859
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
25,664
$
28,008
Accrued liabilities
21,094
25,271
Debt – current
28,504
43,343
Operating lease liabilities – current
3,311
2,905
Deferred revenue
1,433
1,274
Total current liabilities
80,006
100,801
Non-current liabilities:
Debt – non-current
34,846
40,545
Operating lease liabilities – non-current
8,299
10,153
Other non-current liabilities
5,216
5,395
Total liabilities
128,367
156,894
Commitments and contingencies (Note 7)
Stockholders' equity:
Common Stock
202
192
Additional paid-in capital
1,162,386
1,145,343
Accumulated other comprehensive loss
( 602
)
( 156
)
Accumulated deficit
( 1,086,285
)
( 1,081,155
)
Total Cerus Corporation stockholders' equity
75,701
64,224
Noncontrolling interest
661
741
Total liabilities and stockholders' equity
$
204,729
$
221,859
See accompanying Notes to Condensed Consolidated Financial Statements.
1
CERUS CORPORATION CONDENSED CONSOLIDATED S TATEMENTS OF OPERATIONS UNAUDITED
(in thousands, except per share data)
Three Months Ended
Nine Months Ended
September 30,
September 30,
2026
2025
2026
2025
Product revenue
$
57,714
$
52,698
$
168,816
$
148,382
Cost of product revenue
27,449
24,558
81,125
65,843
Gross profit on product revenue
30,265
28,140
87,691
82,539
Government contract revenue
6,304
7,539
18,398
20,
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- SANUWAVE Health SNWV public float $233M, Jun 30, 2025
- Electromed ELMD public float $224M, Dec 31, 2025
- Tactile Systems Technology TCMD public float $223M, Jun 30, 2025
- Orasure Technologies OSUR public float $218M, Jun 30, 2025
- Heartflow HTFL